Type 2 diabetes mellitus and COVID-19: a narrative review

Publication date

2022-10-19T14:32:53Z

2022-10-19T14:32:53Z

2022-08-26

2022-10-19T14:32:53Z

Abstract

Type-2 diabetes mellitus (T2DM) is a chronic metabolic disorder. The incidence and prevalence of patients with T2DM are increasing worldwide, even reaching epidemic values in most high- and middle-income countries. T2DM could be a risk factor of developing complications in other diseases. Indeed, some studies suggest a bidirectional interaction between T2DM and COVID-19. A growing body of evidence shows that COVID-19 prognosis in individuals with T2DM is worse compared with those without. Moreover, various studies have reported the emergence of newly diagnosed patients with T2DM after SARS-CoV-2 infection. The most common treatments for T2DM may influence SARS-CoV-2 and their implication in infection is briefly discussed in this review. A better understanding of the link between TD2M and COVID-19 could proactively identify risk factors and, as a result, develop strategies to improve the prognosis for these patients.

Document Type

Article


Published version

Language

English

Publisher

MDPI

Related items

Reproducció del document publicat a:

Biomedicines, 2022, vol. 10, p. 2089

Recommended citation

This citation was generated automatically.

Rights

cc-by (c) Rey Reñones, Cristina et al., 2022

https://creativecommons.org/licenses/by/4.0/